Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Regains Compliance With Nasdaq Listing Rules

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has regained compliance with the Nasdaq's $1 minimum bid price requirement.

In July, Genetic Technologies said that it had been notified that its shares faced delisting from the exchange for trading below $1 for 30 consecutive business days. The company's stock has now regained listing compliance, having a minimum closing bid price per share of $1 or above for 10 consecutive business days.

During late morning trading, shares of Genetic Technologies were up nearly 12 percent at $1.3869.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.